Pacific Biosciences of California Inc logo

Pacific Biosciences of California Inc

FRA:P09 (USA)  
€ 1.49 (+1.95%) Apr 23
At Loss
P/B:
0.60
Market Cap:
€ 392.21M ($ 419.79M)
Enterprise V:
€ 676.06M ($ 723.59M)
Volume:
750.00
Avg Vol (2M):
5.65K
Also Trade In:
Volume:
750.00
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Pacific Biosciences of California Inc ( FRA:P09 ) from 2010 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Pacific Biosciences of California stock (FRA:P09) PE ratio as of Apr 23 2024 is 0. More Details

Pacific Biosciences of California Inc (FRA:P09) PE Ratio (TTM) Chart

To

Pacific Biosciences of California Inc (FRA:P09) PE Ratio (TTM) Historical Data

Total 1236
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Pacific Biosciences of California PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-24 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-12 At Loss
2024-03-15 At Loss 2024-01-11 At Loss
2024-03-14 At Loss 2024-01-10 At Loss
2024-03-13 At Loss 2024-01-09 At Loss
2024-03-12 At Loss 2024-01-08 At Loss
2024-03-11 At Loss 2024-01-05 At Loss
2024-03-08 At Loss 2024-01-04 At Loss
2024-03-07 At Loss 2024-01-03 At Loss
2024-03-06 At Loss 2024-01-02 At Loss
2024-03-05 At Loss 2023-12-29 At Loss
2024-03-04 At Loss 2023-12-28 At Loss
2024-03-01 At Loss 2023-12-27 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-19 At Loss 2023-12-12 At Loss

Pacific Biosciences of California Inc (FRA:P09) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Pacific Biosciences of California Inc logo
Pacific Biosciences of California Inc
NAICS : 325413 SIC : 3845
ISIN : US69404D1081
Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.